These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1812429)

  • 21. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.
    Borrow R; Aaberge IS; Santos GF; Eudey TL; Oster P; Glennie A; Findlow J; Høiby EA; Rosenqvist E; Balmer P; Martin D
    Clin Diagn Lab Immunol; 2005 Aug; 12(8):970-6. PubMed ID: 16085915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum opsonins to serogroup B meningococci after disease and vaccination.
    Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
    NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.
    Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B
    Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Caugant DA; Frøholm LO; McGuinness BT; Brooks J; Lambden PR; Heckels JE
    Microb Pathog; 1993 Sep; 15(3):197-205. PubMed ID: 7505873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
    Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy.
    Occhionero M; Usai G; Di Martino M; Le Moli S; Stroffolini T; Mastrantonio P
    Allergol Immunopathol (Madr); 1991; 19(1):39-41. PubMed ID: 1950941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.
    Richmond P; Kaczmarski E; Borrow R; Findlow J; Clark S; McCann R; Hill J; Barker M; Miller E
    J Infect Dis; 2000 Feb; 181(2):761-4. PubMed ID: 10669372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
    Balmer P; Borrow R
    Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Humoral immune response to the capsular polysaccharide of Neisseria meningitidis serogroup C in an antimeningococcal BC vaccination trial in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Martínez Ruiz O; Nerey MC; Camarasa MA; Bacallao Gallestey J
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):295-301. PubMed ID: 7779284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
    Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
    Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Humoral immune response to the proteins of an antimeningococcal BC vaccine in a trial carried out in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Blanco González R; Martínez Ruiz O; Martínez Fernández OM; Aguirre Muñoz CA
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):285-94. PubMed ID: 7779283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.
    Oftung F; Naess LM; Wetzler LM; Korsvold GE; Aase A; Høiby EA; Dalseg R; Holst J; Michaelsen TE; Haneberg B
    Infect Immun; 1999 Feb; 67(2):921-7. PubMed ID: 9916109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children.
    Findlow J; Lowe A; Deane S; Balmer P; van den Dobbelsteen G; Dawson M; Andrews N; Borrow R
    Vaccine; 2005 Apr; 23(20):2623-7. PubMed ID: 15780445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.
    Wedege E; Lie K; Bolstad K; Weynants VE; Halstensen A; Herstad TK; Kreutzberger J; Nome L; Naess LM; Aase A
    Scand J Immunol; 2013 Jun; 77(6):452-9. PubMed ID: 23521186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second generation meningococcal OMP-LPS vaccines.
    Poolman JT; van der Ley PA; Wiertz EJ; Hoogerhout P
    NIPH Ann; 1991 Dec; 14(2):233-41. PubMed ID: 1725922
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.